Home > News > Familial Isolated Pituitary Adenomas
Pituitary Disorders
Read Time: 3 mins

Familial Isolated Pituitary Adenomas

Published Online: November 8th 2011 European Endocrinology, 2009; 5:55-8; DOI: http://doi.org/10.17925/EE.2009.05.00.55
Authors: VK Ajith Kumar, M, Harvinder S Chahal
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Abstract
Over the last century several families have been described with familial isolated pituitary adenomas (FIPAs). Most commonly, family members have acromegaly or prolactinoma, but other types of pituitary adenomas can also occur. Recently, mutations in the AIP (aryl hydrocarbon receptor interacting protein) gene have been found to occur in 30–50% of FIPA patients, while for the rest of the patients the gene causing the disease is currently unknown and is a topic of intense research. Tumours in patients with AIP mutations are diagnosed at significantly younger ages and tend to be larger. Often the response to medical therapy in these patients is poor. This article discusses the clinical and genetic characteristics of this relatively recently recognised disease.

Keywords
Pituitary tumour, familial disease, AIP, tumour suppressor gene

Disclosure: The authors have no conflicts of interest to declare.
Acknowledgements: We are very grateful for the helpful advice on the manuscript from one of our patients with familial isolated pituitary adenoma.
Received: 25 April 2009 Accepted: 6 July 2009
Correspondence: Márta Korbonits, Department of Endocrinology, Barts and The London School of Medicine and Dentistry, John Vane Science Centre, Charterhouse Square, London, EC1M 6BQ, UK. E: m.korbonits@qmul.ac.uk

Article:

Pituitary adenomas are common intracranial tumours, and clinically relevant pituitary adenomas have been estimated to occur in about one in every 1,000 of the population. The vast majority of these adenomas are sporadic; however, there is increasing recognition that pituitary adenomas may also occur in a familial setting, and a recent estimate suggests that 5% of pituitary adenomas are familial in origin. Familial pituitary adenomas can form part of the classic syndromes of multiple endocrine neoplasia type 1 (MEN1) and Carney complex.

Pituitary adenomas are common intracranial tumours, and clinically relevant pituitary adenomas have been estimated to occur in about one in every 1,000 of the population. The vast majority of these adenomas are sporadic; however, there is increasing recognition that pituitary adenomas may also occur in a familial setting, and a recent estimate suggests that 5% of pituitary adenomas are familial in origin. Familial pituitary adenomas can form part of the classic syndromes of multiple endocrine neoplasia type 1 (MEN1) and Carney complex. However, a number of families have been identified to have isolated familial pituitary tumours and show an autosomal dominant inheritance with incomplete penetrance (the proportion of individuals with the inherited mutation who develop the disease), without the clinical features or genetic abnormalities of the MEN1 syndrome and Carney complex. Over the last decade, these individuals have been classified as having isolated familial somatotropinoma (IFS),familial isolated pituitary adenoma (FIPA) or pituitary adenoma predisposition (PAP), covering overlapping entities.

The first documented report of families with several members affected by acromegaly occurred over 100 years ago (see Figure 1).8 However, the genetic basis of this condition was unknown until 2006, when a Finnish group identified germline mutations in a gene known as AIP (aryl hydrocarbon receptor interacting protein; see Figure 2) while studying large families with acromegaly and prolactinoma in northern Finland.7 Subsequent work focused on determining the prevalence of AIP mutations in FIPA families and studying the relevance in sporadic pituitary tumours.
FIPA is an autosomal dominant disease with low or variable penetrance (see Figure 3) characterized by a heterogeneous genetic background. FIPA has been identified in more than 170 families, with over 400 individuals described in the literature, including 86 families having familial acromegaly. Within FIPA families there is a heterogeneity of pituitary tumors (see Figure 4),2,6,7,9–11 with somatotroph (growth-hormone-secreting) and lactotroph (prolactin-secreting) adenomas being the most common, although other combinations involving non-functioning adenomas, corticotroph (ACTH-secreting), and gonadotroph (gonadotropin-secreting) adenomas have also been reported.2,12 Patients with familial disease are on average four to six years younger at diagnosis than sporadic patients. Patients from later generations tend to be significantly younger at diagnosis compared with earlier generations, probably because of increased pituitary disease recognition and surveillance among later generations.
Clinical Characteristics of AIP Mutation Patients versus Those with No AIP Mutation
About 20–40% of families with FIPA have a mutation in the AIP gene. Some early-onset—often childhood-onset—acromegaly patients are also positive for AIP mutations. Mutations of AIP have mainly been found in families with either pure somatotroph adenomas or families with mixed somatotroph and lactotroph adenomas. Interestingly, none of the pure prolactinoma families have AIP mutations, and no AIP mutation has been found in a known FIPA family with at least one member not having either a somatotroph or lactotroph adenoma. Pituitary adenoma tissue has also been studied for AIP mutations in cases where the DNA extracted from blood (germline) is negative, but has never revealed any AIP mutations.9,13
Tumors with AIP mutations are diagnosed in subjects at significantly younger ages, and are larger than those found in FIPA patients without AIP mutations, as well as those found in patients with sporadic tumors.9,10,12 Patients with an AIP mutation have a mean age of diagnosis of 25 years compared with 40 years for those without AIP mutations.9,10,12 The youngest patient described as having AIP mutations is six years old (unpublished data), and around two-thirds of patients with AIP mutations are diagnosed at 25 years of age or under.9,10,12 AIP mutation patients have larger pituitary tumors, suggesting more aggressive disease.10 In our cohort, a poor biochemical response to somatostatin analogs (<50% reduction in growth hormone [GH]/ insulin-like growth factor 1 [IGF-I]) occurred in eight of the 15 patients with familial acromegaly.
Due to limited genealogical data, the exact penetrance (proportion of individuals with the mutation who develop the disease) of pituitary tumors is difficult to calculate accurately. However, a best estimate emerges from the largest well-studied family with an AIP mutation: one-third of individuals (three of nine subjects with AIP mutations) developed pituitary tumors at the time of the study.14 We find similar penetrance in our largest family with AIP mutations.

AIP Mutations Described
The AIP protein was thought to be associated with the receptor of an environmental toxin and with a protein important in cyclic adenosine monophosphate (cAMP) degradation (a second messenger signalling molecule in the cell). Currently, it is unclear which mechanism leads to pituitary tumorigenesis in patients with AIP mutations. Forty-one AIP mutations have been identified to date, including deletions, insertions, segmental duplications, non-sense and missense mutations, and large deletions. Mutations usually disrupt the structure of the end of the protein molecule that plays a major role in the functioning of the molecule. Most studies have used sequencing methods with AIP primers covering just the exons and the area around them. However, a new technique called multiplex ligation-dependent probe amplification (MLPA) reveals large genomic rearrangements in families who previously may have tested negative for germline AIP mutations by conventional sequencing.15
Prevalence of AIP Mutations in Familial Isolated Pituitary Adenoma Families
Out of more than 170 FIPA families described in the literature, 30 families have been reported as having 24 different types of AIP mutations. However, the prevalence of AIP mutations is difficult to assess because not all of the reported FIPA families have been sequenced for AIP mutations, and the vast majority were not tested using MLPA. A best estimate is provided by the three largest FIPA family cohorts,7,9–12 suggesting that 20% of all FIPA families have AIP mutations.
Looking only at families with acromegaly, 21 of 53 (40%) families have an AIP mutation.
Prevalence of AIP Mutations in ‘Apparently’ Sporadic Patients
Several studies have searched for AIP mutations in sporadic pituitary adenoma patients, i.e. in patients with no family history of pituitary disease.7,9,11,13,16–24 About 2% of these patients have an AIP mutation in their DNA (27 of 1,100 sporadic pituitary adenoma patients). Most patients with AIP mutations in the ‘apparently’ sporadic cohort have a diagnosis of acromegaly, but there are two reported cases of mutations in patients with Cushing’s disease.11,19
Other Tumors in Familial Isolated Pituitary Adenoma Patients
In our cohort of FIPA families, non-pituitary tumors occur in families with affected patients or obligate AIP mutation carriers: lipomas, breast, thyroid, testicular, renal and bone marrow tumors, anaplastic astrocytomas, primitive neuroectodermal tumors9 and ependymomas (also unpublished data). The association of FIPA with adrenal carcinoma25,26 has also been reported. However, it is unclear whether any of these tumors are part of the FIPA syndrome; further studies are necessary to clarify this.
AIP Mutations in Other Tissues
The role of somatic AIP mutations has previously been studied in the pathogenesis of common cancers (373 colorectal cancers, 82 breast cancers, and 44 prostate tumor samples)27 and 79 endocrine tumors (26 thyroid lesions, 19 adrenal lesions, 16 carcinoids, eight parathyroid lesions, four paragangliomas, four pancreatic endocrine tumors, and two adenocarcinoids).21 No somatic mutations were found, suggesting that AIP is not strongly involved in tumorigenesis in these tumor types.

Tumor-suppressor Role for AIP
Based on clinical data, it has been suggested that FIPAs are caused by a heterozygous germline mutation in a tumor-suppressor gene. Our group has recently captured unique functional data on AIP consistent with a tumor-suppressor role for AIP.9 Cells were transfected with the AIP gene and showed reduced proliferation. On the other hand, when the cell’s own AIP was knocked out, cell proliferation increased.
Practical Relevance to the Clinical Endocrinologist of These Emerging Data About Familial Isolated Pituitary Adenomas
Identifying AIP mutations in patients and carriers is of great clinical importance. Patients with AIP mutations tend to have a more aggressive disease, and treatment can be extremely challenging if diagnosis is late. Genetic testing of relatives of patients with AIP mutations may lead to earlier pituitary tumor detection, thus allowing treatment at an earlier stage. All patients with a family history of pituitary adenoma and no suspicion of MEN1 and Carney complex should undergo genetic counseling and testing for AIP.
If a mutation is found, family members should be screened for the mutation. Carriers should be tested regularly for clinical symptoms and signs and should undergo biochemical and (if necessary) imaging investigations, given that heterologous tumors can occur within families but keeping in mind that incidental tumors of the pituitary are common. If no AIP mutation is found, all family members with a 50% chance of inheriting the disease should be regularly tested. Currently, we are searching for gene(s) causing the disease in AIP-negative families and would like patients with a family history of pituitary adenomas to contact us if they are interested in taking part in the study. Early-onset sporadic pituitary adenomas, especially somatotroph adenomas, have an increased chance of harboring germline AIP mutations, so genetic testing should be considered in these index cases.
Conclusions
AIP has been identified as a novel gene involved in the development of FIPA, especially in those cases involving growth-hormone-secreting tumors, and is probably a tumor-suppressor gene. Mutations in AIP have been found in ~20–40% of families with FIPA. This number will likely increase if all families are tested for large gene deletions. Patients with AIP mutations are diagnosed at younger ages, and their pituitary tumors tend to be larger and more aggressive and respond less well to somatostatin analogs.
Apparently unaffected relatives who are possible carriers require full clinical and biochemical investigation.2 As the majority of FIPA patients do not harbor AIP mutations, and the clinical phenotype (primarily the age at onset and the pituitary tumor type) is different in the AIPmutation- negative families, we think there is a strong possibility that another gene, or genes, may be involved in the pathogenesis of these FIPA cases.

Article Information:

References

  1. Daly AF, Rixhon M, Adam C, et al., High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium, J Clin Endocrinol Metab, 2006;91(12):4769–75.
  2. Beckers A, Daly AF, The clinical, pathological, and genetic features of familial isolated pituitary adenomas, Eur J Endocrinol, 2007;157(4):371–82.
  3. Gadelha MR, Prezant TR, Une KN, et al., Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type I gene, J Clin Endocrinol Metab, 1999;84(1):249–56.
  4. Yamada S, Yoshimoto K, Sano T, et al., Inactivation of the tumor suppressor gene on 11q13 in brothers with familial acrogigantism without multiple endocrine neoplasia type 1, J Clin Endocrinol Metab, 1997;82(1):239–42.
  5. Valdes-Socin H, Betea V, Stevenaert A, Beckers A, Familial isolated pituitary adenomas not related to the MEN-1 syndrome: A study of 27 patients, 10th Meeting of the Belgian Endocrine Society, 2000.
  6. Daly AF, Jaffrain-Rea ML, Ciccarelli A, et al., Clinical characterization of familial isolated pituitary adenomas, J Clin Endocrinol Metab, 2006;91(9):3316–23.
  7. Vierimaa O, Georgitsi M, Lehtonen R, et al., Pituitary adenoma predisposition caused by germline mutations in the AIP gene, Science, 2006;312(5777):1228–30.
  8. Soares BS, Frohman LA, Isolated familial somatotropinoma, Pituitary, 2004;7(2):95–101.
  9. Leontiou CA, Gueorguiev M, van der Spuy SJ, et al., The role of the AIP gene in familial and sporadic pituitary adenomas, J Clin Endocrinol Metab, 2008;93(6):2390–2401.
  10. Daly AF, Vanbellinghen JF, Khoo SK, et al., Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families, J Clin Endocrinol Metab, 2007;92(5):1891–6.
  11. Georgitsi M, Raitila A, Karhu A, et al., Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations, Proc Natl Acad Sci U S A, 2007;104(10):4101–5.
  12. Chahal HS, Igreja SC, Gueorguiev M, et al., The clinical and genetic characteristics of patients with familial isolated pituitary adenomas. Hormones, 11th International Workshop of MEN meeting, Delphi 7, 2008.
  13. Barlier A, Vanbellinghen JF, Daly AF, et al., Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas, J Clin Endocrinol Metab, 2007;92(5):1952–5.
  14. Naves LA, Daly AF, Vanbellinghen JF, et al., Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptorinteracting protein gene, Eur J Endocrinol, 2007;157(4):383–91.
  15. Georgitsi M, Heliovaara E, Paschke R, et al., Large genomic deletions of aryl hydrocarbon receptor interacting protein (AIP) gene in pituitary adenoma predisposition, J Clin Endocrinol Metab, 2008;93(10):4146–51.
  16. Iwata T, Yamada S, Mizusawa N, Golam HM, et al., The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas, Clin Endocrinol (Oxf), 2007;66(4):499–502.
  17. Cazabat L, Libe R, Perlemoine K, et al., Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas, Eur J Endocrinol, 2007;157(1):1–8.
  18. Montanana CF, Daly AF, Tichomirowa MA, et al., Occurrence of AIP mutations in sporadic pituitary adenomas and familial isolated pituitary adenomas kindreds in Valencia, Spain, Proceedings of the 90th Annual Meeting of the Endocrine Society, 2008;P3-775.
  19. Beckers A, Vanbellinghen JF, Boikos S, et al., Germline AIP, MEN1, PRKAR1A, CDKN1B (p27Kip1) and CDKN2C (p18INK4c) gene mutations in a large cohort of pediatric patients with pituitary adenomas occurring in isolation or with associated syndromic features, Proceedings of the 90th Annual Meeting of the Endocrine Society, 2008;OR38-1.
  20. Yaneva M, Daly AF, Tichomirowa MA, et al., Aryl hydrocarbon receptor interacting protein gene mutations in bulgarian FIPA and young sporadic pituitary adenoma patients, Proceedings of the 90th Annual Meeting of the Endocrine Society, 2008;P3-520.
  21. Raitila A, Georgitsi M, Karhu A, et al., No evidence of somatic aryl hydrocarbon receptor interacting protein mutations in sporadic endocrine neoplasia, Endocr Relat Cancer, 2007;14(3):901–6.
  22. Georgitsi M, De ME, Cannavo S, et al., Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas, Clin Endocrinol (Oxf), 2008;69(4):621–7.
  23. Buchbinder S, Bierhaus A, Zorn M, et al., Aryl hydrocarbon receptor interacting protein gene (AIP) mutations are rare in patients with hormone secreting or non-secreting pituitary adenomas, Exp Clin Endocrinol Diabetes, 2008; 116(10):625–8.
  24. Toledo RA, Jallad RS, Fragoso MC, et al., The role of AIP gene in Brazilian patients with sporadic and familial acromegaly, Proceedings of the 90th Annual Meeting of the Endocrine Society, 2008;P3-738.
  25. Luccio-Camelo DC, Une KN, Ferreira RE, et al., A meiotic recombination in a new isolated familial somatotropinoma kindred, Eur J Endocrinol, 2004;150(5):643–8.
  26. Toledo RA, Mendonca BB, Longuini VC, et al., Familial somatotropinoma and adrenocortical carcinoma due to a novel germline mutation and loss of the wild-type allele of the AIP gene, Proceedings of the 90th Annual Meeting of the Endocrine Society, 2008;P1-488.
  27. Georgitsi M, Karhu A, Winqvist R, et al., Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers, Br J Cancer, 2007;96(2):352–6.

Further Resources

Share this Article
Related Content In Pituitary Disorders
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72